If you’re on the fence about investing in Amgen Inc or Pfizer Inc because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision. Read on to ...

(RTTNews) - Amgen Inc. (AMGN) reported earnings for its third quarter that increased from the same period last year and beat the Street estimates. The company's bottom line came in at $2.83 ...

View upcoming earnings forecasts and in-depth analysis of company forecasts.

Amgen Inc.'s Q3 earnings — due 30th October -are unlikely to be a major upside catalyst due to tricky comparisons, increased R&D spending, and transitional phase challenges. Key patents expiring ...

They’re slate-colored birds called Dark-eyed Juncos. “Yes, the Dark-eyed Juncos have arrived,” said Cliff Hagen, Friends of Blue Heron Park vice-president and Protectors of Pine Oak Woods ...

THOUSAND OAKS, Calif., Oct. 25, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.25 per share dividend for the fourth quarter of 2024. The ...

Today, a brief rundown of news from GSK and Amgen, as well as updates from Roche, AbbVie, and Marinus Pharmaceuticals that you may have missed. GSK is making its largest investment in U.S.

If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.

While Regeneron may have lost its latest bid to block the launch of Amgen’s Eylea biosimilar Pavblu, the New York-based pharma isn’t throwing in the towel just yet. At the same time ...

Are you a print subscriber? Activate your account. By Mikey Garcia - 41 min 54 sec ago By Adrianne Pasquarelli - 1 hour 4 min ago By Ad Age and Creativity Staff - 1 hour 13 min ago By Brandon ...

Thousand Oaks, CA-based biotechnology company Amgen has selected IPG Mediabrands to handle its U.S. media agency assignments after a formal review that began earlier this year. Incumbents included ...

Amgen is taking the risky step of preparing to launch a biosimilar version of Regeneron’s blockbuster Eylea drug after winning a victory in an ongoing legal battle. The U.S. Court of Appeals for the ...